NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, Price Target & More

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) posted its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.15. The biotechnology company had revenue of $4.15 million for the quarter, compared to analyst estimates of $11.39 million. Pieris Pharmaceuticals had a negative return on equity of 96.56% and a negative net margin of 65.40%. View Pieris Pharmaceuticals' Earnings History.

5 analysts have issued 12 month target prices for Pieris Pharmaceuticals' stock. Their predictions range from $12.00 to $13.00. On average, they anticipate Pieris Pharmaceuticals' stock price to reach $12.3333 in the next year. This suggests a possible upside of 111.5% from the stock's current price. View Analyst Ratings for Pieris Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Pieris Pharmaceuticals include National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), VIRALYTICS Ltd/S (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Protalex (PRTX), Bioanalytical Systems (BASI) and US Stem Cell (USRM).

News coverage about PIRS stock has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pieris Pharmaceuticals earned a daily sentiment score of 0.12 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 44.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Pieris Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.34%) and Fox Run Management L.L.C. (0.05%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

PIRS stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and Fox Run Management L.L.C.. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PIRS stock can currently be purchased for approximately $5.83.

Pieris Pharmaceuticals has a market capitalization of $314.76 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]